91 results on '"Rigoli R"'
Search Results
2. New onset of loss of smell or taste in household contacts of home-isolated SARS-CoV-2-positive subjects
- Author
-
Boscolo-Rizzo P., Borsetto D., Spinato G., Fabbris C., Menegaldo A., Gaudioso P., Nicolai P., Tirelli G., Da Mosto M. C., Rigoli R., Polesel J., Hopkins C., BOSCOLO RIZZO, PAOLO, Boscolo-Rizzo, P., Borsetto, D., Spinato, G., Fabbris, C., Menegaldo, A., Gaudioso, P., Nicolai, P., Tirelli, G., Da Mosto, M. C., Rigoli, R., Polesel, J., Hopkins, C., and BOSCOLO RIZZO, Paolo
- Subjects
Male ,Taste ,Cross-sectional study ,Olfaction Disorders ,Taste Disorders ,0302 clinical medicine ,Olfaction Disorder ,Prevalence ,Viral ,030223 otorhinolaryngology ,General Medicine ,respiratory system ,Smell ,Taste disorder ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,Coronavirus Infections ,psychological phenomena and processes ,Human ,medicine.medical_specialty ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Short Communication ,Anosmia ,Coronaviru ,Pneumonia, Viral ,Olfaction ,Dysgeusia ,Smell and taste loss ,Household contacts ,03 medical and health sciences ,Betacoronavirus ,Internal medicine ,medicine ,Humans ,Family ,Pandemics ,Cross-Sectional Studie ,Betacoronaviru ,Pandemic ,business.industry ,SARS-CoV-2 ,Coronavirus Infection ,fungi ,COVID-19 ,Pneumonia ,Household contact ,Coronavirus ,Cross-Sectional Studies ,Otorhinolaryngology ,Contact Tracing ,business ,Smell and taste lo ,Contact tracing - Abstract
Purpose To estimate the prevalence of smell or taste impairment in household contacts of mildly symptomatic home-isolated SARS-CoV-2 positive patients.Methods Cross sectional study based on ad hoc questions.Results Of 214 mildly symptomatic COVID-19 patients managed at home under self-isolation, 179 reported to have at least one household contact, with the total number of no study participants contacts being 296. Among 175 household contacts not tested for SARS-CoV-2 infection, 67 (38.3%) had SARS-CoV-2 compatible symptoms, 39 (22.3%) had loss of smell or taste with 7 (4.0%) having loss of smell or taste in the absence of other symptoms. The prevalence of smell or taste impairment was 1.5% in patients tested negative compared to 63.0% of those tested positive for SARS-CoV-2 (pConclusion Smell or taste impairment are quite common in not-tested household contacts of mildly symptomatic home-isolated SARS-CoV-2 positive patients. This should be taken into account when estimating the burden of loss of sense of smell and taste during COVID-19 pandemic, and further highlights the value of loss of sense of smell and taste as a marker of infection.
- Published
- 2020
- Full Text
- View/download PDF
3. West Nile virus transmission through organ transplantation in north-eastern Italy: a case report and implications for pre-procurement screening
- Author
-
Inojosa, W. O., Scotton, P. G., Fuser, R., Giobbia, M., Paolin, A., Maresca, M. C., Brunello, A., Nascimben, E., Sorbara, C., Rigoli, R., Berti, R., Gajo, G. B., and Giometto, B.
- Published
- 2012
- Full Text
- View/download PDF
4. RECOVERY OF GASTRIC FUNCTION AFTER HELICOBACTER PYLORI ERADICATION AND ACETIUM ADMINISTRATION: A 6 YEARS STUDY IN ATROPHIC GASTRITIS SUBJECTS: Abstract no.: P06.03
- Author
-
Di Mario, F., Rugge, M., Ferrara, F., Slongo, T., Dal Boʼ, N., Guarnieri, G., Marcello, R., Salvat, Heras H., Rigoli, R., Dei Tos, A., and Scarpignato, C.
- Published
- 2013
5. Special surveillance of summer fevers in Veneto region, Italy, 2010
- Author
-
Gobbi, F., Capelli, G., Barzon, L., Angheben, A., Pacenti, M., Napoletano, G., Piovesan, C., Montarsi, F., Martini, S., Rigoli, R., Cattelan, A. M., Rinaldi, R., Conforto, M., Russo, F., and Pal, G.
- Published
- 2011
6. Investigation of a Q-fever outbreak in Northern Italy
- Author
-
Manfredi Selvaggi, T., Rezza, G., Scagnelli, M., Rigoli, R., Rassu, M., De Lalla, F., Pellizzer, G. P., Tramarin, A., Bettini, C., Zampieri, L., Belloni, M., Dalla Pozza, E., Marangon, S., Marchiorettos, N., Togni, G., Giacobbo, M., Todescato, A., and Binkin, N.
- Published
- 1996
- Full Text
- View/download PDF
7. Combination of Quinupristin/Dalfopristin and Glycopeptide in Severe Methicillin-Resistant Staphylococcal Infections Failing Previous Glycopeptide Regimens
- Author
-
Scotton, P. G., Rigoli, R., and Vaglia, A.
- Published
- 2002
- Full Text
- View/download PDF
8. Genomics of Klebsiella pneumoniae ST16 producing NDM-1, CTX-M-15, and OXA-232
- Author
-
Espinal, P., primary, Nucleo, E., additional, Caltagirone, M., additional, Mattioni Marchetti, V., additional, Fernandes, M.R., additional, Biscaro, V., additional, Rigoli, R., additional, Carattoli, A., additional, Migliavacca, R., additional, and Villa, L., additional
- Published
- 2019
- Full Text
- View/download PDF
9. Human leptospirosis in the Vicenza area, Italy
- Author
-
Caruso, G., Rigoli, R., Conz, P., Cinco, M., Banfi, E., and de Lalla, F.
- Published
- 1992
- Full Text
- View/download PDF
10. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers
- Author
-
Giani, T, Arena, F, Pollini, S, Di Pilato, V, D'Andrea, Mm, Henrici De Angelis, L, Bassetti, M, Rossolini, Gm, Vismara, C, Luzzaro, F, Cavallo, R, Dusi, Pa, Pagani, E, Sarti, M, Farina, C, Rigoli, R, Scarparo, C, Pecile, P, Cusi, Mg, Mencacci, A, Manso, E, Spanu, Teresa, Labonia, M, Tassi, V, Amato, G, Stefani, S, Giraldi, C, Rassu, M, Spanu T (ORCID:0000-0003-1864-5184), Giani, T, Arena, F, Pollini, S, Di Pilato, V, D'Andrea, Mm, Henrici De Angelis, L, Bassetti, M, Rossolini, Gm, Vismara, C, Luzzaro, F, Cavallo, R, Dusi, Pa, Pagani, E, Sarti, M, Farina, C, Rigoli, R, Scarparo, C, Pecile, P, Cusi, Mg, Mencacci, A, Manso, E, Spanu, Teresa, Labonia, M, Tassi, V, Amato, G, Stefani, S, Giraldi, C, Rassu, M, and Spanu T (ORCID:0000-0003-1864-5184)
- Abstract
Objectives: Pseudomonas aeruginosa is a major cause of severe healthcare-associated infections and often shows MDR phenotypes. Ceftolozane/tazobactam is a new cephalosporin/b-lactamase inhibitor combination with potent activity against P. aeruginosa. This survey was carried out to evaluate the susceptibility of P. aeruginosa, circulating in Italy, to ceftolozane/tazobactam and comparators and to investigate the molecular epidemiology of carbapenemase-producing strains. Methods: Consecutive non-replicate P. aeruginosa clinical isolates (935) from bloodstream infections and lower respiratory tract infections were collected from 20 centres distributed across Italy from September 2013 to November 2014. Antimicrobial susceptibility testing was performed by broth microdilution and results were interpreted according to the EUCAST breakpoints. Isolates resistant to ceftolozane/tazobactam were investigated for carbapenemase genes by PCR, and for carbapenemase activity by spectrophotometric assay. WGS using an Illumina platform was performed on carbapenemase-producing isolates. Results: Ceftolozane/tazobactam was the most active molecule, retaining activity against 90.9% of P. aeruginosa isolates, followed by amikacin (88.0% susceptibility) and colistin (84.7% susceptibility). Overall, 48 isolates (5.1%) were positive for carbapenemase genes, including blaVIM (n"32), blaIMP (n"12) and blaGES-5 (n"4), while the remaining ceftolozane/tazobactam-resistant isolates tested negative for carbapenemase production. Carbapenemase producers belonged to 10 different STs, with ST175 (n"12) and ST621 (n"11) being the most common lineages. Genome analysis revealed different trajectories of spread for the different carbapenemase genes. Conclusions: Ceftolozane/tazobactam exhibited potent in vitro activity against P. aeruginosa causing invasive infections in Italy. Carbapenemase production was the most common mechanism of resistance to ceftolozane/ tazobactam.
- Published
- 2018
11. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey
- Author
-
Girmenia, C, Bertaina, A, Piciocchi, A, Perruccio, K, Algarotti, A, Busca, A, Cattaneo, C, Raiola, Am, Guidi, S, Iori, Ap, Candoni, A, Irrera, G, Milone, G, Marcacci, G, Scimè, R, Musso, M, Cudillo, L, Sica, S, Castagna, L, Corradini, P, Marchesi, F, Pastore, D, Alessandrino, Ep, Annaloro, C, Ciceri, F, Santarone, S, Nassi, L, Farina, C, Viscoli, C, Rossolini, Gm, Bonifazi, F, Rambaldi, A, Capria, S, Mastronuzzi, A, Pagliara, D, Bernaschi, P, Amico, L, Carotti, A, Mencacci, A, Bruno, B, Costa, C, Passi, A, Ravizzola, G, Angelucci, E, Marchese, A, Pecile, P, Ventura, G, Fanin, R, Scarparo, C, Barbaro, A, Leotta, S, Marchese, Ae, Becchimanzi, C, Donnarumma, D, Tringali, S, Baldi, Mt, Scalone, R, Picardi, A, Arcese, W, Fontana, C, Giammarco, S, Spanu, T, Crocchiolo, R, Casari, E, Mussetti, A, Conte, E, Ensoli, F, Miragliotta, G, Marone, P, Arghittu, M, Greco, R, Forcina, A, Chichero, P, Di Bartolomeo, P, Fazii, P, Kroumova, V, Decembrino, N, Zecca, M, Pisapia, G, Palazzo, G, Lanino, E, Faraci, M, Castagnola, E, Bandettini, R, Pastano, R, Sammassimo, S, Passerini, R, Stefani, Pm, Gherlinzoni, F, Rigoli, R, Prezioso, L, Cambò, B, Calderaro, A, Carella, Am, Cascavilla, N, Labonia, Mt, Celeghini, I, Mordini, N, Piana, F, Vacca, A, Sanna, M, Podda, G, Corsetti, Mt, Rocchetti, A, Cilloni, D, De Gobbi, M, Bianco, O, Fagioli, F, Carraro, F, De Intinis, G, Severino, A, Proia, A, Parisi, G, Vallisa, D, Confalonieri, M, Russo, D, Malagola, M, Galieni, P, Falcioni, S, Travaglini, V, Raimondi, R, Borghero, C, Pavan, G, Prete, A, Belotti, T, Ambretti, S, Imola, M, Mianulli, Am, Pedna, Mf, Cesaro, S, Lo Cascio, G, Ferrari, A, Piedimonte, M, Santino, I, Calandrelli, M, Olivieri, A, Orecchioni, F, Mirabile, M, Centurioni, R, Gironacci, L, Caravelli, D, Gallo, S, De Filippi, M, Cupelli, L, Dentamaro, T, Falco, S, Eugenio, Os, Marotta, S, Risitano, A, Lula, D, Musto, P, Pietrantuono, G, Traficante, A, Cerchiara, E, Tirindelli, Mc, Dicuonzo, G, Chierichini, A, Anaclerico, B, and Placanica, P.
- Published
- 2017
12. Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia after Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey
- Author
-
Girmenia, C., Bertaina, A., Piciocchi, A., Perruccio, K., Algarotti, A., Busca, A., Cattaneo, C., Raiola, A. M., Guidi, S., Iori, A. P., Candoni, A., Irrera, G., Milone, G., Marcacci, G., Scime, R., Musso, M., Cudillo, L., Sica, Simona, Castagna, Luigi, Corradini, P., Marchesi, F., Pastore, D., Alessandrino, E. P., Annaloro, C., Ciceri, F., Santarone, S., Nassi, L., Farina, C., Viscoli, C., Rossolini, G. M., Bonifazi, F., Rambaldi, A., Capria, S., Mastronuzzi, A., Pagliara, D., Bernaschi, P., Amico, L., Carotti, A., Mencacci, A., Bruno, Brunella, Costa, C., Passi, A., Ravizzola, G., Angelucci, E., Marchese, Alessandra Maria, Pecile, P., Ventura, Giulio, Fanin, R., Scarparo, C., Barbaro, A., Leotta, Salvatore Nuccio, Marchese, A. E., Becchimanzi, C., Donnarumma, D., Tringali, S., Baldi, M. T., Scalone, R., Picardi, A., Arcese, W., Fontana, Cecilia Alejandra, Giammarco, S., Spanu, Teresa, Crocchiolo, R., Casari, E., Mussetti, A., Conte, Eliana, Ensoli, F., Miragliotta, G., Marone, P., Arghittu, M., Greco, R., Forcina, A., Chichero, P., Di Bartolomeo, P., Fazii, P., Kroumova, V., Decembrino, N., Zecca, M., Pisapia, Giovanni, Palazzo, G., Lanino, E., Faraci, M., Castagnola, E., Bandettini, R., Pastano, R., Sammassimo, S., Passerini, R., Stefani, P. M., Gherlinzoni, F., Rigoli, R., Prezioso, L., Cambo, B., Calderaro, A., Carella, A. M., Cascavilla, N., Labonia, M. T., Celeghini, I., Mordini, N., Piana, F., Vacca, A., Sanna, Maria Maddalena, Podda, G., Corsetti, M. T., Rocchetti, A., Cilloni, D., De Gobbi, M., Bianco, O., Fagioli, F., Carraro, F., De Intinis, G., Severino, A., Proia, Anna Silvia, Parisi, G., Vallisa, D., Confalonieri, Marco, Russo, D., Malagola, M., Galieni, P., Falcioni, S., Travaglini, V., Raimondi, Maria Rosa, Borghero, C., Pavan, Giuseppe, Prete, A., Belotti, T., Ambretti, S., Imola, M., Mianulli, A. M., Pedna, M. F., Cesaro, S., Lo Cascio, G., Ferrari, A., Piedimonte, M., Santino, I., Calandrelli, M., Olivieri, Alessandra, Orecchioni, F., Mirabile, M., Centurioni, R., Gironacci, L., Caravelli, D., Gallo, S., De Filippi, M., Cupelli, L., Dentamaro, T., Falco, S., Eugenio, O. S., Marotta, S., Risitano, A., Lula, D., Musto, P., Pietrantuono, G., Traficante, A., Cerchiara, E., Tirindelli, M. C., Dicuonzo, G., Chierichini, A., Anaclerico, B., Placanica, P., Sica S. (ORCID:0000-0003-2426-3465), Castagna L., Bruno B., Marchese A., Ventura G. (ORCID:0000-0002-0304-7264), Leotta S., Fontana C., Spanu T. (ORCID:0000-0003-1864-5184), Conte E., Pisapia G., Sanna M., Proia A., Confalonieri M. (ORCID:0000-0002-3708-379X), Raimondi R., Pavan G., Olivieri A., Girmenia, C., Bertaina, A., Piciocchi, A., Perruccio, K., Algarotti, A., Busca, A., Cattaneo, C., Raiola, A. M., Guidi, S., Iori, A. P., Candoni, A., Irrera, G., Milone, G., Marcacci, G., Scime, R., Musso, M., Cudillo, L., Sica, Simona, Castagna, Luigi, Corradini, P., Marchesi, F., Pastore, D., Alessandrino, E. P., Annaloro, C., Ciceri, F., Santarone, S., Nassi, L., Farina, C., Viscoli, C., Rossolini, G. M., Bonifazi, F., Rambaldi, A., Capria, S., Mastronuzzi, A., Pagliara, D., Bernaschi, P., Amico, L., Carotti, A., Mencacci, A., Bruno, Brunella, Costa, C., Passi, A., Ravizzola, G., Angelucci, E., Marchese, Alessandra Maria, Pecile, P., Ventura, Giulio, Fanin, R., Scarparo, C., Barbaro, A., Leotta, Salvatore Nuccio, Marchese, A. E., Becchimanzi, C., Donnarumma, D., Tringali, S., Baldi, M. T., Scalone, R., Picardi, A., Arcese, W., Fontana, Cecilia Alejandra, Giammarco, S., Spanu, Teresa, Crocchiolo, R., Casari, E., Mussetti, A., Conte, Eliana, Ensoli, F., Miragliotta, G., Marone, P., Arghittu, M., Greco, R., Forcina, A., Chichero, P., Di Bartolomeo, P., Fazii, P., Kroumova, V., Decembrino, N., Zecca, M., Pisapia, Giovanni, Palazzo, G., Lanino, E., Faraci, M., Castagnola, E., Bandettini, R., Pastano, R., Sammassimo, S., Passerini, R., Stefani, P. M., Gherlinzoni, F., Rigoli, R., Prezioso, L., Cambo, B., Calderaro, A., Carella, A. M., Cascavilla, N., Labonia, M. T., Celeghini, I., Mordini, N., Piana, F., Vacca, A., Sanna, Maria Maddalena, Podda, G., Corsetti, M. T., Rocchetti, A., Cilloni, D., De Gobbi, M., Bianco, O., Fagioli, F., Carraro, F., De Intinis, G., Severino, A., Proia, Anna Silvia, Parisi, G., Vallisa, D., Confalonieri, Marco, Russo, D., Malagola, M., Galieni, P., Falcioni, S., Travaglini, V., Raimondi, Maria Rosa, Borghero, C., Pavan, Giuseppe, Prete, A., Belotti, T., Ambretti, S., Imola, M., Mianulli, A. M., Pedna, M. F., Cesaro, S., Lo Cascio, G., Ferrari, A., Piedimonte, M., Santino, I., Calandrelli, M., Olivieri, Alessandra, Orecchioni, F., Mirabile, M., Centurioni, R., Gironacci, L., Caravelli, D., Gallo, S., De Filippi, M., Cupelli, L., Dentamaro, T., Falco, S., Eugenio, O. S., Marotta, S., Risitano, A., Lula, D., Musto, P., Pietrantuono, G., Traficante, A., Cerchiara, E., Tirindelli, M. C., Dicuonzo, G., Chierichini, A., Anaclerico, B., Placanica, P., Sica S. (ORCID:0000-0003-2426-3465), Castagna L., Bruno B., Marchese A., Ventura G. (ORCID:0000-0002-0304-7264), Leotta S., Fontana C., Spanu T. (ORCID:0000-0003-1864-5184), Conte E., Pisapia G., Sanna M., Proia A., Confalonieri M. (ORCID:0000-0002-3708-379X), Raimondi R., Pavan G., and Olivieri A.
- Abstract
Background Gram-negative bacteremia (GNB) is a major cause of illness and death after hematopoietic stem cell transplantation (HSCT), and updated epidemiological investigation is advisable. Methods We prospectively evaluated the epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs (auto-HSCTs) among 54 transplant centers during 2014 (SIGNB-GITMO-AMCLI study). Using logistic regression methods. we identified risk factors for GNB and evaluated the impact of GNB on the 4-month overall-survival after transplant. Results The cumulative incidence of pre-engraftment GNB was 17.3% in allo-HSCT and 9% in auto-HSCT. Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa were the most common isolates. By multivariate analysis, variables associated with GNB were a diagnosis of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and duration of severe neutropenia in allo-HSCT, and a diagnosis of lymphoma, older age, and no antibacterial prophylaxis in auto-HSCT. A pretransplant infection by a resistant pathogen was significantly associated with an increased risk of posttransplant infection by the same microorganism in allo-HSCT. Colonization by resistant gram-negative bacteria was significantly associated with an increased rate of infection by the same pathogen in both transplant procedures. GNB was independently associated with increased mortality at 4 months both in allo-HSCT (hazard ratio, 2.13; 95% confidence interval, 1.45-3.13; P <.001) and auto-HSCT (2.43; 1.22-4.84; P =.01). Conclusions Pre-engraftment GNB is an independent factor associated with increased mortality rate at 4 months after auto-HSCT and allo-HSCT. Previous infectious history and colonization monitoring represent major indicators of GNB. Clinical Trials registration NCT02088840.
- Published
- 2017
13. Human and entomological surveillance of West Nile fever, dengue and chikungunya in Veneto Region, Italy, 2010-2012
- Author
-
Bisoffi, Zeno, Capelli, G, Angheben, A, Giobbia, M, Conforto, M, Franzetti, M, Cattelan, Am, Raise, E, Rovere, P, Mulatti, P, Montarsi, F, Drago, A, Barzon, L, Napoletano, G, Zanella, F, Pozza, F, Russo, F, Rosi, P, Palù, G, Bisoffi, Z, Summer Fever Study Group, Concia, Ercole, Francavilla, E, Marranconi, F, Pellizzer, G, Scotton, P, Sgarabotto, D, Brugnaro, P, Del Bravo, P, Ferretto, R, Masini, G, Mondardini, V, Viviani, F, Piovesan, C, Postiglione, C, Cattai, M, Conti, A, Cusinato, R, Degani, M, Forti, A, Franchin, E, Gion, M, Marcante, R, Modolo, E, Pacenti, M, Rassu, M, Rigoli, R, Scarin, M, and Tonolli, Elisabetta
- Subjects
Adult ,Male ,Veterinary medicine ,Aedes albopictus ,Adolescent ,viruses ,Dengue virus ,Biology ,medicine.disease_cause ,West Nile ,Dengue fever ,Dengue ,Young Adult ,Culex pipiens ,medicine ,Animals ,Humans ,Chikungunya ,Horses ,Alphavirus infection ,Aged ,Aged, 80 and over ,Travel ,Surveillance ,Alphavirus Infections ,Outbreak ,virus diseases ,Dengue Virus ,Middle Aged ,medicine.disease ,biology.organism_classification ,Virology ,Insect Vectors ,Infectious Diseases ,Culicidae ,Italy ,Epidemiological Monitoring ,Chikungunya Fever ,Female ,Horse Diseases ,Chikungunya virus ,West Nile virus ,Malaria ,West Nile Fever ,Research Article - Abstract
Background Since 2010 Veneto region (North-Eastern Italy) planned a special integrated surveillance of summer fevers to promptly identify cases of West Nile Fever (WNF), dengue (DENV) and chikungunya (CHIKV). The objectives of this study were (i) To increase the detection rate of imported CHIKV and DENV cases in travellers from endemic areas and promptly identify potential autochthonous cases.(ii) To detect autochthonous cases of WNF, besides those of West Nile Neuroinvasive Disease (WNND) that were already included in a national surveillance. Methods Human surveillance: a traveler who had returned within the previous 15 days from endemic countries, with fever >38°C, absence of leucocytosis (leukocyte count 38°C for
- Published
- 2013
14. European Confederation of Medical Mycology (ECMM) prospective survey of cryptococcosis: Report from Italy
- Author
-
Viviani, Ma, Antinori, S, Cogliati, M, Esposto, Mc, Pinsi, G, Casari, S, Bergamasco, A, De Santis Ml, Ghirga, P, Bonaccorso, C, Jacchetti, G, Niero, F, Ammassari, A, Morace, G, Ossi, C, Montagna, Mt, Angarano, G, Farina, C, Maggiolo, F, Moroni, M, Pierdomenico, S, Michelone, G, Cavanna, C, Viti, F, Carli, T, Barchiesi, F, Agrappi, C, Mena, M, Giola, M, Lombardi, G, Tinelli, M, Ceraminiello, A, Codeluppi, M, Casolari, C, Foresti, S, Bramati, S, Ruggieri, A, Caggese, L, Astolfi, A, Bonora, S, Scotton, Pg, Rigoli, R, Angioni, G, Meneghetti, F, Nullg, Nulldi Perri, UBERTI FOPPA, CATERINA, Viviani, Ma, Antinori, S, Cogliati, M, Esposto, Mc, Pinsi, G, Casari, S, Bergamasco, A, De Santis, Ml, Ghirga, P, Bonaccorso, C, Jacchetti, G, Niero, F, Ammassari, A, Morace, G, UBERTI FOPPA, Caterina, Ossi, C, Montagna, Mt, Angarano, G, Farina, C, Maggiolo, F, Moroni, M, Pierdomenico, S, Michelone, G, Cavanna, C, Viti, F, Carli, T, Barchiesi, F, Agrappi, C, Mena, M, Giola, M, Lombardi, G, Tinelli, M, Ceraminiello, A, Codeluppi, M, Casolari, C, Foresti, S, Bramati, S, Ruggieri, A, Caggese, L, Astolfi, A, Bonora, S, Scotton, Pg, Rigoli, R, Angioni, G, Meneghetti, F, and Nullg, Nulldi Perri
- Abstract
Italy is one of the countries participating in a prospective epidemiological survey of cryptococcosis set up in July 1997 by the European Confederation of Medical Mycology (ECMM). Over a 30-month period 156 cases, all caused by Cryptococcus neoformans var. neoformans, were reported by 29 hospitals in 9 regions. An ECMM questionnaire was used to report the clinical presentation and the diagnostic and treatment approach used. Cryptococcosis was associated with HIV infection in 147 cases and was considered indicative of AIDS in 65%. The estimated incidence in the Lombardy region was 0.85/100 in the AIDS population. One isolate from each of 129 patients was serotyped and genotyped. PCR fingerprinting using the primer (GACA)(4) proved to be a more reproducible typing method than the slide agglutination test. Genotypes VN1 (serotype D), VN6 (serotype A) and VN3-VN4 (serotype AD hybrid strains) occurred in Italy at similar levels nationwide, but VN1 (D) was prevalent in the North. In vitro resistance to antifungals was uncommon.
- Published
- 2002
15. Special surveillance of summer fevers in Veneto region, Italy, 2010
- Author
-
Gobbi, F, Capelli, G, Barzon, Luisa, Angheben, A, Pacenti, Monia, Napoletano, G, Piovesan, C, Montarsi, F, Martini, S, Rigoli, R, Cattelan, Am, Rinaldi, R, Conforto, M, Russo, F, and Palu', Giorgio
- Published
- 2011
16. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy
- Author
-
Tempera, Gianna, Furneri, Pio Maria, Carlone, Na, Cocuzza, C, Rigoli, R, Musumeci, R, Pilloni, Ap, Prenna, M, Tufano, Ma, Tullio, V, Vitali, La, and Nicoletti, G.
- Published
- 2010
17. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei
- Author
-
Drago, M., Scaltrito, M. M., Morace, G., Manso, E., Paladini, C., Montagna, M. T., Tato’, D., Goglio, A., Farina, C., Nanetti, A., Morelli, S., Sanna, M., Podda, R., Porcu, P. P., Oliveri, S., Buscema, G., Nicoletti, P. L., Pecile, P., Schito, G. C., Soro, O., Viviani, M. A., Tortorano, A. M., Amato, G., Piccirillo, M. M., Cione, P., Cuccurullo, S., Andreoni, S., Fanello, M. R., Menozzi, M., DI STEFANO, E., Polonelli, L., Conti, S., Fanti, F., Cavanna, P. MARONE C., Bistoni, F., Mencacci, A., Pitzurra, L., Sergi, D., Barbaro, P., Fadda, G., Sanguinetti, M., Rigoli, R., Niero, M., Lombardi, G. L., Coli’, A., Fontana, Roberta, and LO CASCIO, Giuliana
- Subjects
Microbiology (medical) ,Antifungal Agents ,Candida glabrata ,Candida krusei ,Sensititre YeastOne-3 system ,Itraconazole ,Microbial Sensitivity Tests ,Pharmacology ,In Vitro Techniques ,Sensitivity and Specificity ,Sampling Studies ,Flucytosine ,Microbiology ,Drug Resistance, Fungal ,Amphotericin B ,medicine ,Humans ,Candida ,chemistry.chemical_classification ,Voriconazole ,biology ,Candidiasis ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,Triazoles ,bacterial infections and mycoses ,biology.organism_classification ,stomatognathic diseases ,Infectious Diseases ,Pyrimidines ,chemistry ,Italy ,Azole ,Fluconazole ,medicine.drug - Abstract
The antifungal susceptibility of 309 Candida glabrata and 63 Candida krusei clinical isolates was tested via the Sensititre YeastOne-3 system (Trek Diagnostic Systems, East Grinstead, UK) to compare the in vitro activity of voriconazole with that of five other antifungal agents (amphotericin B, fluconazole, itraconazole, ketoconazole, and flucytosine). Voriconazole was highly active (MIC90, 0.5 microg/ml) against isolates of both species, including those for which the MICs of itraconazole and fluconazole were high (MIC90s of itraconazole, 2 microg/ml for C. glabrata and 0.5 microg/ml for C. krusei; MIC90s of fluconazole, 32 microg/ml for C. glabrata and 64 microg/ml for C. krusei). Ketoconazole MIC90 values for both species were identical to those of voriconazole. The MIC90 of amphotericin B was similar for both species (0.125 microg/ml for C. glabrata and 0.25 microg/ml for C. krusei). As expected, flucytosine was only moderately active against C. krusei isolates (MIC90, 16 microg/ml) but was highly active against C. glabrata isolates (MIC90, 0.03 microg/ml). Potential cross-resistance within the azole class was noted for some strains of C. glabrata (5.5%) that presented high MIC values for all the azoles tested. In order to consider voriconazole a viable alternative to other triazoles for the treatment of infections caused by Candida species, susceptibility testing of all clinically significant isolates of C. glabrata and C. krusei is recommended because of the potential for azole cross-resistance. The Sensititre YeastOne-3 seems to be a suitable commercial tool for this purpose.
- Published
- 2005
18. Voriconazole activity against clinical yeast isolates: a multicentre Italian study
- Author
-
Morace, G, Polonelli, L., Amato, G., Piccirillo, M., Belli, C. M. C., Andreoni, S., Fanello, R., Barbaro, P., Petraroli, C., Bistoni, F., Mencacci, A., Pitzurra, L., Cione, P., Fadda, G., Sanguinetti, M., Fontana, Roberta, LO CASCIO, Giuliana, Goglio, A., Farina, C., Lombardi, G., Coli', A., Manso, E., Paladini, C., Marone, P., Cavanna, C., Menozzi, M., DI STEFANO, E., Montagna, M. T., Napoli, C., Tato', D., Nanatti, A., Nicoletti, P. L., Pecile, P., Oliveri, S., Buscema, G., Conti, S., Fanti, F., Rigoli, R., Niero, M., Sanna, M., Podda, R., Porcu, P. P., Schito, G. C., Soro, O., Viviani, M. A., Tortorano, A. M., LA FACE, S., and Mancuso, I.
- Subjects
Microbiology (medical) ,Antifungal Agents ,Comparative methods ,Voriconazole ,Yeast susceptibility testing ,Drug resistance ,Microbial Sensitivity Tests ,Saccharomyces cerevisiae ,Biology ,Microbiology ,Trichosporon ,Drug Resistance, Fungal ,Outpatients ,medicine ,Humans ,Pharmacology (medical) ,Agar diffusion test ,Candida albicans ,Diffusion methods ,Etest ,Candida ,Inpatients ,Broth microdilution ,Fungi ,General Medicine ,Triazoles ,bacterial infections and mycoses ,biology.organism_classification ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,Geotrichum ,Yeast ,Infectious Diseases ,Pyrimidines ,Italy ,Mycoses ,Cryptococcus neoformans ,medicine.drug - Abstract
The activity of voriconazole was tested in vitro against 1996 clinical yeast isolates collected in 20 Italian microbiology laboratories. Voriconazole susceptibility testing was carried out with the broth microdilution (NCCLS M27-A2), Etest and disk diffusion methods. The minimum inhibitory concentrations at which 90% of the isolates were inhibited (MIC90) obtained with the NCCLS method were 0.03 mg/L for Candida albicans, 0.5 mg/L for Candida non-albicans and 0.25 mg/L for other genera; those obtained with Etesting were, respectively, 0.032 mg/L, 0.125 mg/L and 0.125 mg/L. With the disk diffusion method, the majority of isolates (92.3%) showed inhibition zone diameters between 21 mm and 40 mm. Using a tentative MIC cut-off of 1 mg/L as indicative of in vitro susceptibility, 98.1% of the isolates tested in our study would be classified as susceptible, and only 28 (1.4%) of the isolates, with MICs higher than 2 mg/L, would be classified as resistant to the drug. Our findings confirm the broad-spectrum in vitro activity of voriconazole against yeasts, including Candida species that are generally less susceptible to other azoles.
- Published
- 2005
19. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on cefditoren
- Author
-
Tempera, G, Furneri, P, Carlone, N, Cocuzza, C, Rigoli, R, Musumeci, R, Pilloni, A, Prenna, M, Tufano, M, Tullio, V, Vitali, L, Nicoletti, G, Furneri, PM, Carlone, NA, Pilloni, AP, Tufano, MA, Vitali, LA, Nicoletti, G., COCUZZA, CLEMENTINA ELVEZIA, MUSUMECI, ROSARIO, Tempera, G, Furneri, P, Carlone, N, Cocuzza, C, Rigoli, R, Musumeci, R, Pilloni, A, Prenna, M, Tufano, M, Tullio, V, Vitali, L, Nicoletti, G, Furneri, PM, Carlone, NA, Pilloni, AP, Tufano, MA, Vitali, LA, Nicoletti, G., COCUZZA, CLEMENTINA ELVEZIA, and MUSUMECI, ROSARIO
- Abstract
The aim of this study was to evaluate the in vitro antibiotic susceptibility of respiratory pathogens recently isolated in Italy to commonly used antibiotics including cefditoren. Six clinical microbiological laboratories collected, between January and September 2009, a total of 2,510 respiratory pathogens from subjects with community-acquired respiratory tract infections (CARTI). Ceftditoren, out of all the beta-lactams studied, had the lowest MIC(90 )against 965 strains of Streptococcus pneumoniae examined, followed by cefotaxime and ceftriaxone (2% resistance in penicillin-resistant S. pneumoniae (PRSP)). Against 470 Haemophilus influenzae , independently of their production of beta-lactamases or ampicillin resistance, cefditoren was the oral cephalosporin with the best in vitro activity, comparable to that of the injectable cephalosporins and levofloxacin. Higher MIC(90)s were found for the macrolides (4 - 16 mg/l) and cefaclor (4 - 32 mg/l). As was foreseeable, Streptococcus pyogenes (225 strains) was uniformly sensitive to all the beta-lactam antibiotics, but the elevated MIC(90 )values reduced (<75%) susceptibility of this pathogen to macrolides. Beta-lactamase-negative Moraxella catarrhalis (100 strains) had reduced susceptibility only to the macrolides, while the 250 beta-lactamase-producing strains also had reduced susceptibility to cefuroxime. Levofloxacin showed the lowest MIC(50)/MIC(90 )values in the producing strains, whereas cefditoren, cefotaxime and ceftriaxone in the non-producers. As regards the enterobacteriaceae, cefditoren and levofloxacin had the lowest MIC(90)s against Klebsiella pneumoniae. Cefditoren and the third-generation injectable cephalosporins had the lowest MIC(90)s against Escherichia coli (100% susceptibility) while levofloxacin was less active (86% susceptibility).In conclusion, cefditoren's wide spectrum and high intrinsic activity, as well as its capacity to overcome most of the resistance that has become consolidated in some
- Published
- 2010
20. P.09.1 RECOVERY OF GASTRIC FUNCTION AFTER HELICOBACTER PYLORI ERADICATION AND ACETIUM ADMINISTRATION: A 6 YEARS STUDY IN ATROPHIC GASTRITIS SUBJECTS
- Author
-
Di Mario, F., primary, Rugge, M., additional, Ferrara, F., additional, Dal Bò, N., additional, Slongo, T., additional, Guarnieri, G., additional, Marcello, R., additional, Salvat, H. Heras, additional, Caroli, A., additional, Rigoli, R., additional, Dei Tos, A.P., additional, and Scarpignato, C., additional
- Published
- 2013
- Full Text
- View/download PDF
21. P.09.22 GASTROPANEL, A NON-INVASIVE, SAFE ENDOSCOPY METHOD: A PROSPECTIVE 1000 PATIENTS STUDY IN PRIMARY CARE SETTING
- Author
-
Ferrara, F., primary, Franceschet, I., additional, Rigoli, R., additional, Pascoli, S., additional, Slongo, T., additional, Dal Bò, N., additional, Caroli, A., additional, Marcello, R., additional, Scarpignato, C., additional, Schiavinato, A., additional, and Di Mario, F., additional
- Published
- 2013
- Full Text
- View/download PDF
22. PREVALENCE OF FLUOROQUINOLONE RESISTANCE IN EUROPE
- Author
-
KRESKEN, M HAFNER, D MITTERMAYER, H VERBIST, L and BERGOGNEBEREZIN, E GIAMARELLOU, H ESPOSITO, S VANKLINGEREN, B KAYSER, FH REEVES, DS WIEDEMANN, B ROTTER, M and WEWALKA, G AICHINGER, W BREITFELLNER, G SCHINDLER, J and STRATCHUNSKY, L LAUWERS, S OSTERRIETH, P VERSCHRAEGEN, G and VANLANDYT, H MERTENS, A KARTLEVEN, J POTVLIEGHE, C and FUSSLE, R LUTTICKEN, R HOPKEN, MS FABRICIUS, K WERNER, H and ULLMANN, U NICULESCU, ER LANGMAACK, H RINGELMANN, R and MACHKA, K OPFERKUCH, W DASCHNER, F MANNHEIM, W WAGNER, J and ROHR, HP SCHAFER, V WITTE, W KELLER, P NAUMANN, G and HUOVINEN, P AVRIL, P BEBEAR, P DABERNAT, H DRUGEON, P DUVAL, P FLEURETTE, P GROSSET, P MONTEIL, H and SCHEFTEL, JP THABAUT, P VERON, M AVLAMIS, A KATRACHOURA, A KOUMENTAKOU, I PAPOUTSAKI, L BARON, F RIGOLI, R and DELALLA, F SCARPELLINI, P BALDELLI, F CANZANO, G and CASERTA, I ORTISI, T MAGLIANO, E ROZENBERGARSKA, M and WAGENVOORT, JHT DEGENER, J VANGRIETHYSEN, AJA HEINZER, I and PEDUZZI, R PIFFORETTI, JC MUNZINGER, J ARDER, HP and SCHOPFER, K BREER, C BILLE, J SIEGRIST, H AUCKENTHALER, R MODDE, H FREY, R BODMER, T WISE, R SPENCER, R and FELMINGHAM, D GOLDIERO, F
- Abstract
Since 1984, when the first fluoroquinolone, norfloxacin, was marketed in Europe, there has been a marked increase in the usage of this class of drugs. In order to evaluate the influence of this drug usage on the prevalence of resistance to fluoroquinolones in clinical isolates of the family Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcuss aureus, coagulase-negative staphylococci and Enterococcus faecalis we reviewed the susceptibility data from four collaborative surveys conducted between 1983 and 1990 by the Study Group ‘Bacterial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. All participating laboratories used the same standardized methods. Miminal inhibitory concentrations were determined by the broth microdilution method. More than 20,000 bacterial strains were tested. The results are presented for ciprofloxacin, which is regarded as the representative of the fluoroquinolones. Using greater than or equal to 4 mg/l as a breakpoint for resistance to ciprofloxacin, the prevalence of resistant strains of the family Enterobacteriaceae in Central Europe between 1983 and 1990 remained below 1%. In contrast, the resistance rates in P. aeruginosa were 0.7%, 1.0%, 3.8% and 7.0%, in S. aureus 0%, 0.5%, 6.6% and 6.8%, and in E. faecalis 2.2%, 0.7%, 4.9% and 7.7% in 1983, 1986, 1989 and 1990, respectively. The latest study carried out in cooperation with 78 laboratories from 12 European countries revealed great differences in the prevalence of resistance to fluoroquinolones from one species to another ranging from 0% with Proteus vulgaris and Salmonella spp. to 26.7% with Providencia stuartii. The highest rates of resistance were recorded for oxacillin-resistant strains of S. aureus (70.6%) and oxacillin-resistant coagulase-negative staphylococci (51.2%). Resistance levels for individual species varied between countries, but they were consistently higher in Southern Europe than in Northwest and Central Europe. Resistance in S. aureus and E. faecalis was more prevalent in isolates from intensive care patients than in isolates from patients on normal wards. In addition, S. aureus isolates displayed a considerable difference in the resistance rates for blood (9.3%) and urine (34.4%).
- Published
- 1994
23. Sensibilità in vitro dei batteri Gram positivi di maggiore rilevanza clinica, Studio multicentrico
- Author
-
Baldelli, F., Baron, F., Bonadio, M., Canzano, G., Caserta, S., de Lalla, F., Esposito, Silvano, Galdiero, F., Magliano, E., Noviello, S., Ortisi, G., Rigoli, R., and Scarpellini, P.
- Published
- 1994
24. Antibiotic Susceptibility of Respiratory Pathogens Recently Isolated in Italy: Focus on Cefditoren
- Author
-
Tempera, G., primary, Furneri, P.M., additional, Carlone, N.A., additional, Cocuzza, C., additional, Rigoli, R., additional, Musumeci, R., additional, Pilloni, A.P., additional, Prenna, M., additional, Tufano, M.A., additional, Tullio, V., additional, Vitali, L.A., additional, and Nicoletti, G., additional
- Published
- 2010
- Full Text
- View/download PDF
25. Multicenter Comparative Evaluation of Six Commercial Systems and the National Committee for Clinical Laboratory Standards M27-A Broth Microdilution Method for Fluconazole Susceptibility Testing of Candida Species
- Author
-
Morace, G., primary, Amato, G., additional, Bistoni, F., additional, Fadda, G., additional, Marone, P., additional, Montagna, M. T., additional, Oliveri, S., additional, Polonelli, L., additional, Rigoli, R., additional, Mancuso, I., additional, La Face, S., additional, Masucci, L., additional, Romano, L., additional, Napoli, C., additional, Tatò, D., additional, Buscema, M. G., additional, Belli, C. M. C., additional, Piccirillo, M. M., additional, Conti, S., additional, Covan, S., additional, Fanti, F., additional, Cavanna, C., additional, D'Alò, F., additional, and Pitzurra, L., additional
- Published
- 2002
- Full Text
- View/download PDF
26. Rhodococcus equi Nosocomial Meningitis Cured by Levofloxacin and Shunt Removal
- Author
-
Scotton, P. G., primary, Tonon, E., additional, Giobbia, M., additional, Gallucci, M., additional, Rigoli, R., additional, and Vaglia, A., additional
- Published
- 2000
- Full Text
- View/download PDF
27. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea
- Author
-
de Lalla, F, primary, Nicolin, R, additional, Rinaldi, E, additional, Scarpellini, P, additional, Rigoli, R, additional, Manfrin, V, additional, and Tramarin, A, additional
- Published
- 1992
- Full Text
- View/download PDF
28. Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS
- Author
-
de Lalla, F, primary, Maserati, R, additional, Scarpellini, P, additional, Marone, P, additional, Nicolin, R, additional, Caccamo, F, additional, and Rigoli, R, additional
- Published
- 1992
- Full Text
- View/download PDF
29. Epidemiology and outcome of Clostridium difficile infections in patients hospitalized in Internal Medicine: findings from the nationwide FADOI-PRACTICE study
- Author
-
Cioni, Giorgio, Viale, Pierluigi, Frasson, Stefania, Cipollini, Francesco, Menichetti, Francesco, Petrosillo, Nicola, Brunati, Sergio, Spigaglia, Patrizia, Vismara, Chiara, Bielli, Alessandra, Barbanti, Fabrizio, Landini, Giancarlo, Panigada, Grazia, Gussoni, Gualberto, Bonizzoni, Erminio, Gesu, Giovanni Pietro, Costantino, A., Masciari, R., Amato, G., Fontanella, A., Gallucci, F., Improta, L., Poggiano, M. R., Rabitti, P., Uomo, G., Civardi, G., Confalonieri, M., Grandi, M., Sacchetti, C., Baldini, T., Cioni, G., Miglioli, S., Sarti, M., Landini, M. P., Panuccio, D., Romboli, E., Vocale, C., Berti, F., Bonito, L., Gozzo, M. L., Manfellotto, D., Natili, S., Patti, A., Piccolo, P., Pistella, E., Santini, C., Pastorelli, R., Pellegrinotti, M., Quaratino, C. P., Bona, R., Gnerre, P., Lillo, F., Parodi, L., Bovero, A., Santoriello, L., Agnelli, F., Colombo, F., Gesu, G., Lombardi, G., Lanzetti, V., Biagiotti, S., Clerici, P., Mazzone, A., Brusco, G., Magnani, L., Tirella, S., Terulla, C., Manso, E., Nitti, C., Salvi, A., Ciarambino, T., Pepe, C., Politi, C., Frediani, R., Moschella, A., Lodolo, L., Barasolo, G., Bertoncelli, M. C., Milano, F., Campanini, M., Molinari, G. L., Pittau, S., De Bernochi, A., Giusti, M., Montegrosso, G., Errico, M., Mastroianni, F., Tauro, L., Caddori, A., Prasciolu, C. G., Di Naso, C., Romano, M., D'Angelo, A., Genco, L., Mangano, G., Arena, F., Biagioni, C., Cimolato, B., Landini, G., Nozzoli, C., Poli, A., Rossolini, G., Burzigotti, F., Francioni, S., Lenti, S., Galanti, I. A., Belcari, C., Longo, B., Salamone, D., Chiti, I., Lencioni, P., Panigada, G., Teghini, L., Gambacorta, M., Perrotta, U., Battaglia, G., Pizzato, E., Vian, A., De Menis, E., Bordignon, G., Tramontin, P., Doroldi, C., Ravagnan, P., Sartore, P., Leoni, M., Pauletto, P., Rigoli, R., Callegari, C., Sacchetta, A., Vendrame, A., Cioni G, Viale P, Frasson S, Cipollini F, Menichetti F, Petrosillo N, Brunati S, Spigaglia P, Vismara C, Bielli A, Barbanti F, Landini G, Panigada G, Gussoni G, Bonizzoni E, and Gesu G P
- Subjects
Diarrhea ,Male ,medicine.medical_specialty ,genetic structures ,medicine.drug_class ,Antibiotics ,Real-Time Polymerase Chain Reaction ,lcsh:Infectious and parasitic diseases ,Immunoenzyme Techniques ,03 medical and health sciences ,0302 clinical medicine ,Medical microbiology ,Clostridium difficile ,Incidence ,Internal Medicine ,Outcome ,Predictors ,Aged ,Aged, 80 and over ,Anti-Bacterial Agents ,Clostridium Infections ,Female ,Hospital Mortality ,Humans ,Italy ,Length of Stay ,Middle Aged ,Prospective Studies ,Infectious Diseases ,Internal medicine ,Epidemiology ,medicine ,80 and over ,lcsh:RC109-216 ,030212 general & internal medicine ,Prospective cohort study ,Clostridioides difficile ,business.industry ,Incidence (epidemiology) ,clostridium difficile ,incidence ,internal medicine ,outcome ,predictors ,aged ,aged, 80 and over ,anti-bacterial agents ,clostridioides difficile ,clostridium infections ,diarrhea ,female ,hospital mortality ,humans ,immunoenzyme techniques ,length of stay ,male ,middle aged ,prospective studies ,real-time polymerase chain reaction ,Tropical medicine ,clostridium difficile GDH EPIDEMIOLOGY ,030211 gastroenterology & hepatology ,medicine.symptom ,business ,Research Article - Abstract
Background Clostridium difficile (CD) is a leading cause of diarrhoea among hospitalized patients. The objective of this study was to evaluate the rate, the optimal diagnostic work-up, and outcome of CD infections (CDI) in Internal Medicine (IM) wards in Italy. Methods PRACTICE is an observational prospective study, involving 40 IM Units and evaluating all consecutive patients hospitalized during a 4-month period. CDI were defined in case of diarrhoea when both enzyme immunoassay for GDH, and test for A/B toxin were positive. Patients with CDI were followed-up for recurrences for 4 weeks after the end of therapy. Results Among the 10,780 patients observed, 103 (0.96 %) showed CDI, at admission or during hospitalization. A positive history for CD, antibiotics in the previous 4 weeks, recent hospitalization, female gender and age were significantly associated with CDI (multivariable analysis). In-hospital mortality was 16.5 % in CD group vs 6.7 % in No-CD group (p
- Full Text
- View/download PDF
30. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: The GISIA-2 study
- Author
-
Morace, G., Drago, M., Scaltrito, M. M., Conti, S., Fanti, F., Polonelli, L., Amato, G., Piccirillo, M., Belli, M. C. M., Andreoni, S., Fanello, R., Barbaro, P., Petraroli, C., Bistoni, F., Mencacci, A., Pitzurra, L., Cione, P., Cuccurullo, S., Fadda, G., Sanguinetti, M., Fontana, R., Lo Cascio, G., Goglio, A., Farina, C., Lombardi, G., Colì, A., Manso, E., Paladini, C., Marone, P., Cavanna, C., Menozzi, M., Di Stefano, E., Montagna, M. T., christian napoli, Tatò, D., Nanetti, A., Nicoletti, P. L., Pecile, P., Oliveri, S., Buscema, G., Rigoli, R., Niero, M., Sanna, M., Podda, R., Porcu, P. P., Schito, G. C., Soro, O., Viviani, M. A., Tortorano, A. M., La Face, S., and Mancuso, I.
- Subjects
Antifungal Agents ,medicine.drug_class ,Itraconazole ,Antibiotics ,Aspergillus flavus ,Microbial Sensitivity Tests ,In Vitro Techniques ,Microbiology ,Minimum inhibitory concentration ,MIC-MFC ,amphotericin B, Voriconazole, mould susceptibility, itraconazole, MIC-MFC ,Drug Resistance, Fungal ,Amphotericin B ,polycyclic compounds ,medicine ,Humans ,Pharmacology (medical) ,Pharmacology ,Voriconazole ,Aspergillus ,mould susceptibility ,biology ,Broth microdilution ,Fungi ,Triazoles ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,biology.organism_classification ,amphotericin B ,itraconazole ,Pyrimidines ,Infectious Diseases ,Mycoses ,Oncology ,medicine.drug - Abstract
We evaluated the in vitro activity of voriconazole, amphotericin B, and itraconazole against 192 clinical mould isolates recovered in twenty Italian microbiology laboratories. The vast majority of isolates belonged to the genus Aspergillus (94.2%) with A. fumigatus (58.3%) being the most frequently isolated species. Antifungal susceptibility testing was performed using the broth microdilution method defined by the CLSI M38-A standard, and results were compared to those obtained with Sensititre panels. Aspergillus flavus ATCC 204304 was employed as reference strain and results were within all expected ranges. Voriconazole's activity against the 192 mould isolates was comparable to that of amphotericin B and itraconazole: voriconazole MIC90 (CLSI 1 microg/ml, Sensititre 1 microg/ml), itraconazole MIC90 (CLSI 0.5 microg/ml, Sensititre 0.5 microg/ml), amphotericin B MIC90 (CLSI 1 microg/ml, Sensititre 1 microg/ml). In conclusion, these in vitro data highlight voriconazole's broad spectrum activity against filamentous fungi and support its use as a first line agent for the treatment of fungal diseases.
31. Competitive potential of wheat Cultivars as affected by emergence time,Potencial competitivo de cultivares de trigo em função do tempo de emergência
- Author
-
Rigoli, R. P., Agostinetto, D., Vaz Da Silva, J. M. B., Fontana, L. C., and Leandro Vargas
32. Antifungal susceptibility of invasive yeast isolates in Italy: the GISIA3 study in critically ill patients
- Author
-
Mussap Michele, Manso Ester, Lombardi Gianluigi, Cascio Giuliana, Farina Claudio, Brigante Gioconda, Andreoni Stefano, Amato Gerardino, Iatta Roberta, Borghi Elisa, Morace Giulia, Pecile Patrizia, Rigoli Roberto, Tangorra Elisabetta, Valmarin Maria, and Montagna Maria
- Subjects
Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background Yeasts are a common cause of invasive fungal infections in critically ill patients. Antifungal susceptibility testing results of clinically significant fungal strains are of interest to physicians, enabling them to adopt appropriate strategies for empiric and prophylactic therapies. We investigated the antifungal susceptibility of yeasts isolated over a 2-year period from hospitalised patients with invasive yeast infections. Methods 638 yeasts were isolated from the blood, central venous catheters and sterile fluids of 578 patients on general and surgical intensive care units and surgical wards. Etest strips and Sensititre panels were used to test the susceptibility of the isolates to amphotericin B, anidulafungin, caspofungin, fluconazole, itraconazole, posaconazole and voriconazole in 13 laboratories centres (LC) and two co-ordinating centres (CC). The Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method was used at the CCs for comparison. Results Etest and Sensititre (LC/CC) MIC90 values were, respectively: amphotericin B 0.5/0.38, 1/1 mg/L; anidulafungin 2/1.5 and 1/1 mg/L; caspofungin 1/0.75 and 0.5/0.5 mg/L; fluconazole 12/8 and 16/16 mg/L; itraconazole 1/1.5, 0.5/0.5 mg/L; posaconazole 0.5 mg/L and voriconazole 0.25 mg/L for all. The overall MIC90 values were influenced by the reduced susceptibility of Candida parapsilosis isolates to echinocandins and a reduced or lack of susceptibility of Candida glabrata and Candida krusei to azoles, in particular fluconazole and itraconazole. Comparison of the LC and CC results showed good Essential Agreement (90.3% for Etest and 92.9% for Sensititre), and even higher Categorical Agreement (93.9% for Etest and 96% for Sensititre); differences were observed according to the species, method, and antifungal drug. No cross-resistance between echinocandins and triazoles was detected. Conclusions Our data confirm the different antifungal susceptibility patterns among species, and highlight the need to perform antifungal susceptibility testing of clinically relevant yeasts. With the exception of a few species (e.g. C. glabrata for azoles and C. parapsilosis for echinocandins), the findings of our study suggest that two of the most widely used commercial methods (Etest and Sensititre) provide valid and reproducible results.
- Published
- 2011
- Full Text
- View/download PDF
33. Community Use of Face Masks against the Spread of COVID-19
- Author
-
Luciano Bubbico, Luca Cegolon, Claudio Gisabella, Marco Capelli, Mohammad Javanbakht, Roberto Rigoli, Francesca Larese-Filon, Giuseppe Mastrangelo, Salvatore Ferlito, Martina Maurelli, Paolo Basso, Saverio Bellizzi, Bubbico, L., Mastrangelo, G., Larese-Filon, F., Basso, P., Rigoli, R., Maurelli, M., Ferlito, S., Capelli, M., Gisabella, C., Javanbakht, M., Bellizzi, S., and Cegolon, L.
- Subjects
Coronavirus disease 2019 (COVID-19) ,Health, Toxicology and Mutagenesis ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,COVID-19 ,Face masks ,Health protection ,Nasal cavity ,SARS-CoV-2 ,Transmissibility ,Humans ,Masks ,Virus Diseases ,Viral transmission ,lcsh:Medicine ,transmissibility ,nasal cavity ,health protection ,face masks ,Biology ,03 medical and health sciences ,Face mask ,0302 clinical medicine ,030212 general & internal medicine ,Cold weather ,030304 developmental biology ,0303 health sciences ,Innate immune system ,Mask ,lcsh:R ,Public Health, Environmental and Occupational Health ,Physical Barrier ,Viral replication ,Immunology ,Commentary ,Human - Abstract
The role of face masks to prevent and control COVID-19 is critical, especially since asymptomatic or pre-symptomatic infected individuals can shed high loads of SARS-CoV-2 in the surrounding environment. In addition to being a two-way barrier to protect against virions droplets both in terms of “source control” (for the benefits of the community) and “physical protection” (for wearer), face masks also allow maintaining physiological temperatures and humidity of the nasal cavity and mouth, independently from the external environmental conditions. Beyond compromising the viral transmission speed, exposure to cold environments could have a detrimental effect on the host’s susceptibility to SARS-CoV-2. The innate human immune system becomes in fact weaker with cooler nose temperatures and thus more vulnerable to viral replication. Furthermore, there is evidence that warm, humid climates are associated with reduced spread of SARS-CoV-2, while cold dry conditions favor its stability and transmissibility. In the early stage of a viral infection, a physiological body temperature in the upper airways supports the innate immune system, endorsing the muco-ciliary clearance, inhibiting, or deactivating any first settlement of viruses. Face masks are therefore strongly recommended also outdoors, especially under cold weather conditions, not only as a physical barrier against the transmission of SARS-CoV-2, but also to prevent the rapid cooling of the nasal mucosa and the inhibition of the human innate defense of the upper airways.
- Published
- 2021
34. Association between hepatitis C and B viruses and head and neck squamous cell carcinoma
- Author
-
Jonathan Fussey, Daniele Borsetto, Paolo Boscolo-Rizzo, Elisa Vian, Anna Menegaldo, Giacomo Spinato, Valeria Biscaro, Roberto Rigoli, Maria Cristina Da Mosto, Sara Donà, Jerry Polesel, Dona, S., Borsetto, D., Fussey, J., Biscaro, V., Vian, E., Spinato, G., Menegaldo, A., Da Mosto, M. C., Rigoli, R., Polesel, J., and Boscolo-Rizzo, P.
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,Hepatitis B virus ,medicine.medical_specialty ,Epidemiology ,030106 microbiology ,Hepacivirus ,Antibodies, Viral ,Young Adult ,03 medical and health sciences ,Hepatitis B, Chronic ,0302 clinical medicine ,Risk Factors ,Virology ,Internal medicine ,Prevalence ,medicine ,Carcinoma ,Humans ,Hepatitis C infection ,030212 general & internal medicine ,Head and neck cancer ,Case-control study ,Hepatitis B infection ,Aged ,Retrospective Studies ,Hepatitis ,Squamous Cell Carcinoma of Head and Neck ,business.industry ,Incidence ,Hepatitis C ,Hepatitis C, Chronic ,Middle Aged ,Hepatitis B ,medicine.disease ,Head and neck squamous-cell carcinoma ,Non-Hodgkin's lymphoma ,stomatognathic diseases ,Infectious Diseases ,Italy ,Head and Neck Neoplasms ,Case-Control Studies ,Hepatocellular carcinoma ,Female ,business - Abstract
Background Hepatitis B and C viruses are known to be carcinogenic and have been associated with the development of non-Hodgkin’s lymphoma as well as hepatocellular carcinoma. The incidence of head and neck cancer is increasing worldwide, and early diagnosis is vital in order to achieve good oncological outcomes. Objectives To investigate the association between chronic hepatitis B and C infection, and head and neck squamous cell carcinoma (HNSCC). Study design We performed a retrospective case control study with 774 head and neck squamous cell carcinoma (HNSCC) patients undergoing treatment, and 1518 cancer-free controls undergoing hernia surgery. Hepatitis B and C serologies were tested prior to treatment, and cases and controls were age- and sex-matched before analysing rates of infection. Results HNSCC patients were more likely than controls to have evidence of chronic hepatitis B (OR = 2.76; CI 95 %, 1.64–4.64) and hepatitis C (OR = 2.59; 95 % CI, 1.46–4.60) infection. No substantial association was found between hepatitis B and C infection and other known risk factors for head and neck cancer. Conclusions These findings suggest a positive association between both hepatitis B and hepatitis C chronic infection, and HNSCC. More work is needed to establish a causal role, however an awareness of the possibility of increased risk of HNSCC may lead to earlier diagnosis and better outcomes in patients with hepatitis B and C.
- Published
- 2019
- Full Text
- View/download PDF
35. A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy
- Author
-
Assunta Sartor, Piergiorgio Cojutti, Federico Pea, Claudio Scarparo, Paola Coato, Roberto Rigoli, Cojutti P., Scarparo C., Sartor A., Coato P., Rigoli R., and Pea F.
- Subjects
Longitudinal Studie ,Minocycline ,Tigecycline ,MRSA ,medicine.disease_cause ,chemistry.chemical_compound ,Acetamides ,Longitudinal Studies ,Teicoplanin ,Methicillin-Resistant Staphylococcus aureu ,Microbial Sensitivity Test ,Broth microdilution ,Glycopeptides ,General Medicine ,Staphylococcal Infections ,Health Survey ,Oxazolidinone ,Anti-Bacterial Agents ,Infectious Diseases ,Blood ,Italy ,Staphylococcus aureus ,Vancomycin ,medicine.drug ,Human ,Methicillin-Resistant Staphylococcus aureus ,Microbiology (medical) ,Microbial Sensitivity Tests ,Glycopeptide ,Microbiology ,Daptomycin ,Anti-Bacterial Agent ,medicine ,Humans ,Bacteraemia ,Oxazolidinones ,Staphylococcal Infection ,business.industry ,Linezolid ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,Health Surveys ,Methicillin-resistant Staphylococcus aureus ,chemistry ,business ,Acetamide - Abstract
A 5-year survey (2009-2013) of antimicrobial susceptibility of methicillin-resistant Staphylococcus aureus (MRSA) isolated from patients with bloodstream infections was carried out in Northeast Italy. No upward creep of glycopeptides MICs was documented among 582 nonduplicate MRSA blood isolates, which were tested in accordance with broth microdilution and interpreted in accordance with EUCAST recommendations. Teicoplanin showed stably a lower MIC50 in comparison with vancomycin (0.25-0.5 versus 1 mg/L). The activities of newer anti-MRSA antibacterials stratified by glycopeptides MICs showed similar trends in MICs of either vancomycin or teicoplanin with those of daptomycin, linezolid, and tigecycline. We hypothesize that in centers with different distribution of glycopeptides MICs, downward for teicoplanin and upward for vancomycin, teicoplanin could be a more effective alternative to vancomycin for empirical treatment of MRSA-related bacteremia.
- Published
- 2015
36. West Nile virus transmission through organ transplantation in north-eastern Italy: a case report and implications for pre-procurement screening
- Author
-
A. Brunello, W. O. Inojosa, M. Giobbia, Pier Giorgio Scotton, R. Rigoli, M. C. Maresca, R. Berti, G. B. Gajo, R. Fuser, C. Sorbara, E. Nascimben, A. Paolin, B. Giometto, Inojosa, Wo, Scotton, Pg, Fuser, R, Giobbia, M, Paolin, A, Maresca, Mc, Brunello, A, Nascimben, E, Sorbara, C, Rigoli, R, Berti, R, Gajo, Gb, and Giometto, B
- Subjects
Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,West Nile virus ,animal diseases ,viruses ,Transplants ,medicine.disease_cause ,Antibodies, Viral ,Organ transplantation ,Medicine ,Humans ,Coma ,West Nile Virus Infection ,Transplantation ,business.industry ,Transmission (medicine) ,virus diseases ,General Medicine ,medicine.disease ,Virology ,Tissue Donors ,nervous system diseases ,Infectious Diseases ,Italy ,RNA, Viral ,Female ,business ,Encephalitis ,West Nile Fever - Abstract
Purpose West Nile virus (WNV) transmission through organ transplantation occurs rarely and screening of organ donors for WNV infection remains controversial. This report describes the case of WNV encephalitis in a kidney recipient and the case of asymptomatic WNV infection in the organ donor, both observed at Treviso Hospital, northeastern Italy. After briefly reviewing the literature, we discuss the implications for WNV screening. Methods We reviewed medical, laboratory and epidemiological records at our hospital, and the literature concerning cases of organ-transmitted WNV infections and WNV screening of organ donors in Italy and worldwide. Results The kidney recipient was the first confirmed case of WNV infection notified in northeastern Italy in 2011, and the first case of WNV infection in a cluster of four transplant recipients who acquired the infection from a common organ donor. The organ donor, whose WNV infection was only retrospectively diagnosed by IgM detection, represents the index case of a WNV outbreak in the Treviso Province. Screening of her blood prior to organ recovery did not show detectable levels of WNV nucleic acid with the use of quantitative real-time polymerase chain reaction. Conclusions This report emphasizes that transplant-acquired WNV neuroinvasive disease can be particularly severe. We suggest that pre-procurement screening of organ donors by testing blood with both WNV IgM capture ELISA and a sensitive nucleic acid testing should be adopted during the transmission season in the present Italian epidemiological setting.
- Published
- 2011
37. Antibiotic susceptibility of respiratory pathogens recently isolated in Italy: focus on ceftidoren
- Author
-
Rosario Musumeci, R Rigoli, Ma Tufano, Clementina Cocuzza, Giuseppe Nicoletti, Viviana Cristina Tullio, La Vitali, Furneri Pm, Gianna Tempera, Manuela Prenna, Nicola Carlone, Ap Pilloni, Tempera, G, Furneri, P, Carlone, N, Cocuzza, C, Rigoli, R, Musumeci, R, Pilloni, A, Prenna, M, Tufano, M, Tullio, V, Vitali, L, and Nicoletti, G
- Subjects
Cefotaxime ,Microbial Sensitivity Tests ,medicine.disease_cause ,Microbiology ,Amp resistance ,Levofloxacin ,Ampicillin ,Streptococcus pneumoniae ,Gram-Negative Bacteria ,polycyclic compounds ,medicine ,Humans ,Pharmacology (medical) ,Respiratory Tract Infections ,Pharmacology ,Respiratory tract infections ,business.industry ,biochemical phenomena, metabolism, and nutrition ,Anti-Bacterial Agents ,Cephalosporins ,Community-Acquired Infections ,Infectious Diseases ,Oncology ,Italy ,MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA ,business ,Gram-Negative Bacterial Infections ,Cefditoren ,Cefaclor ,cefditoren, antibiotic susceptibility ,medicine.drug - Abstract
The aim of this study was to evaluate the in vitro antibiotic susceptibility of respiratory pathogens recently isolated in Italy to commonly used antibiotics including cefditoren. Six clinical microbiological laboratories collected, between January and September 2009, a total of 2,510 respiratory pathogens from subjects with community-acquired respiratory tract infections (CARTI). Ceftditoren, out of all the beta-lactams studied, had the lowest MIC(90 )against 965 strains of Streptococcus pneumoniae examined, followed by cefotaxime and ceftriaxone (2% resistance in penicillin-resistant S. pneumoniae (PRSP)). Against 470 Haemophilus influenzae , independently of their production of beta-lactamases or ampicillin resistance, cefditoren was the oral cephalosporin with the best in vitro activity, comparable to that of the injectable cephalosporins and levofloxacin. Higher MIC(90)s were found for the macrolides (4 - 16 mg/l) and cefaclor (4 - 32 mg/l). As was foreseeable, Streptococcus pyogenes (225 strains) was uniformly sensitive to all the beta-lactam antibiotics, but the elevated MIC(90 )values reduced (75%) susceptibility of this pathogen to macrolides. Beta-lactamase-negative Moraxella catarrhalis (100 strains) had reduced susceptibility only to the macrolides, while the 250 beta-lactamase-producing strains also had reduced susceptibility to cefuroxime. Levofloxacin showed the lowest MIC(50)/MIC(90 )values in the producing strains, whereas cefditoren, cefotaxime and ceftriaxone in the non-producers. As regards the enterobacteriaceae, cefditoren and levofloxacin had the lowest MIC(90)s against Klebsiella pneumoniae. Cefditoren and the third-generation injectable cephalosporins had the lowest MIC(90)s against Escherichia coli (100% susceptibility) while levofloxacin was less active (86% susceptibility).In conclusion, cefditoren's wide spectrum and high intrinsic activity, as well as its capacity to overcome most of the resistance that has become consolidated in some classes of antibiotics widely used as empiric therapy for CARTI, allows us to suggest that cefditoren might be included in the european guidelines as one of the first-choice antibiotics in the treatment of CARTI.
- Published
- 2010
38. Radiomics and Artificial Intelligence Can Predict Malignancy of Solitary Pulmonary Nodules in the Elderly.
- Author
-
Elia S, Pompeo E, Santone A, Rigoli R, Chiocchi M, Patirelis A, Mercaldo F, Mancuso L, and Brunese L
- Abstract
Solitary pulmonary nodules (SPNs) are a diagnostic and therapeutic challenge for thoracic surgeons. Although such lesions are usually benign, the risk of malignancy remains significant, particularly in elderly patients, who represent a large segment of the affected population. Surgical treatment in this subset, which usually presents several comorbidities, requires careful evaluation, especially when pre-operative biopsy is not feasible and comorbidities may jeopardize the outcome. Radiomics and artificial intelligence (AI) are progressively being applied in predicting malignancy in suspicious nodules and assisting the decision-making process. In this study, we analyzed features of the radiomic images of 71 patients with SPN aged more than 75 years (median 79, IQR 76-81) who had undergone upfront pulmonary resection based on CT and PET-CT findings. Three different machine learning algorithms were applied-functional tree, Rep Tree and J48. Histology was malignant in 64.8% of nodules and the best predictive value was achieved by the J48 model (AUC 0.9). The use of AI analysis of radiomic features may be applied to the decision-making process in elderly frail patients with suspicious SPNs to minimize the false positive rate and reduce the incidence of unnecessary surgery.
- Published
- 2023
- Full Text
- View/download PDF
39. Chest radiography findings of COVID-19 pneumonia: a specific pattern for a confident differential diagnosis.
- Author
-
Landini N, Colzani G, Ciet P, Tessarin G, Dorigo A, Bertana L, Felice C, Scaldaferri L, Orlandi M, Nardi C, Romagnoli M, Saba L, Rigoli R, and Morana G
- Subjects
- Humans, SARS-CoV-2, Diagnosis, Differential, Tomography, X-Ray Computed methods, Radiography, Lung diagnostic imaging, Radiography, Thoracic methods, Retrospective Studies, COVID-19 diagnostic imaging, Pleural Effusion
- Abstract
Background: Chest radiography (CR) patterns for the diagnosis of COVID-19 have been established. However, they were not ideated comparing CR features with those of other pulmonary diseases., Purpose: To create the most accurate COVID-19 pneumonia pattern comparing CR findings of COVID-19 and non-COVID-19 pulmonary diseases and to test the model against the British Society of Thoracic Imaging (BSTI) criteria., Material and Methods: CR of COVID-19 and non-COVID-19 pulmonary diseases, admitted to the emergency department, were evaluated. Assessed features were interstitial opacities, ground glass opacities, and/or consolidations and the predominant lung alteration. We also assessed uni-/bilaterality, location (upper/middle/lower), and distribution (peripheral/perihilar), as well as pleural effusion and perihilar vessels blurring. A binary logistic regression was adopted to obtain the most accurate CR COVID-19 pattern, and sensitivity and specificity were computed. The newly defined pattern was compared to BSTI criteria., Results: CR of 274 patients were evaluated (146 COVID-19, 128 non-COVID-19). The most accurate COVID-19 pneumonia pattern consisted of four features: bilateral alterations (Expß=2.8, P =0.002), peripheral distribution of the predominant (Expß=2.3, P =0.013), no pleural effusion (Expß=0.4, P =0.009), and perihilar vessels' contour not blurred (Expß=0.3, P =0.002). The pattern showed 49% sensitivity, 81% specificity, and 64% accuracy, while BSTI criteria showed 51%, 77%, and 63%, respectively., Conclusion: Bilaterality, peripheral distribution of the predominant lung alteration, no pleural effusion, and perihilar vessels contour not blurred determine the most accurate COVID-19 pneumonia pattern. Lower field involvement, proposed by BSTI criteria, was not a distinctive finding. The BSTI criteria has lower specificity.
- Published
- 2022
- Full Text
- View/download PDF
40. COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge.
- Author
-
Furlan A, Forner G, Cipriani L, Vian E, Rigoli R, Gherlinzoni F, and Scotton P
- Subjects
- COVID-19 Vaccines, Humans, Antigens, CD20 immunology, B-Lymphocytes immunology, COVID-19 diagnosis, COVID-19 immunology, COVID-19 prevention & control, Immunologic Factors therapeutic use, Rituximab therapeutic use, SARS-CoV-2, COVID-19 Drug Treatment
- Abstract
B cell-targeting strategies such as rituximab are widely used in B cell hematologic malignancies, rheumatologic and musculoskeletal diseases and a variety of autoimmune disorders. The purpose of this paper is to illustrate how exposure to anti-CD20 treatment profoundly affects B cell functions involved in anti-SARS-CoV-2 immunity and significantly impacts on the clinical and serological course of SARS-CoV-2 infection, long term immunity and vaccine responses. The data presented here suggest that the effects of B cell-depleting agents on adaptive immunity should be taken into account for the proper selection and interpretation of SARS-CoV-2 diagnostics and to guide appropriate therapeutic approaches and protective measures. Combination therapeutic strategies including immunotherapy in association with prolonged antiviral treatment may play a decisive role in the setting of B cell immune deficiencies., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Furlan, Forner, Cipriani, Vian, Rigoli, Gherlinzoni and Scotton.)
- Published
- 2021
- Full Text
- View/download PDF
41. Suppression of Covid-19 outbreak among healthcare workers at the Treviso Regional Hospital, Italy and lessons for ophthalmologists.
- Author
-
Grosso A, Rigoli R, Formentini S, Di Perri G, Scotton P, Dapavo G, Fioretto M, and Scarpa G
- Subjects
- Disease Outbreaks, Health Personnel, Hospitals, Humans, Italy epidemiology, SARS-CoV-2, COVID-19, Ophthalmologists
- Abstract
Purpose: To describe a strategy to reduce Covid-19 spread among healthcare workers and provide ophthalmologists with recommendations useful for a possible second wave of Covid-19 in Autumn., Methods: Epidemiological surveillance at the Cà Foncello Hospital (Veneto, Italy) since 24 February 2020 to 24 April 2020 when the municipality of Treviso was hit by the Covid-19 outbreak. The number of naso-pharigeal (NP) swabs performed was 7010., Results: The number of infected among healthcare workers was 209/ 3924 (5.32%): medical doctors: 28 cases / 498 (5.6%). None among ophthalmologists; specialized nurses: 86/1294 (6.4%) None in the ophthalmic unit; intermediate care technicians: 68/463 (14.7%). The 46% of the positive tested were asymptomatic. We share key suggested actions for the reorganization in ophthalmological services: be part of a global epidemiological local strategy of containment (Testing, Tracing, Treating); protect your department: Keep on screening patients by telephone interview before entering the hospital; promote continuous and appropriate use of PPE both for doctors and for patients; make any effort to obtain a continuous flow of patients in every line of the ophthalmic service; treat appropriately any single patient with vision threatening condition; avoid unnecessary or futile testings and examinations., Conclusion: The Treviso model shows that it is possible and safe to keep on performing high risk hospital activities like ophthalmology, even in the epicenter of covid outbreak, if adequate actions are performed. We discuss about the value of NP swabs and serological tests as a strategy in case of a second wave of infections.
- Published
- 2021
- Full Text
- View/download PDF
42. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.
- Author
-
Furlan A, Forner G, Cipriani L, Vian E, Rigoli R, Gherlinzoni F, and Scotton P
- Subjects
- Adenosine Monophosphate administration & dosage, Alanine administration & dosage, B-Lymphocytes pathology, COVID-19 complications, Combined Modality Therapy, Drug Administration Schedule, Humans, Immunization, Passive methods, Immunocompromised Host, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Italy, Lymphoma, Non-Hodgkin complications, Lymphoma, Non-Hodgkin pathology, Lymphopenia etiology, Lymphopenia pathology, Lymphopenia therapy, Male, Middle Aged, Pneumonia, Viral complications, Pneumonia, Viral therapy, Rituximab adverse effects, SARS-CoV-2 physiology, Treatment Outcome, COVID-19 Drug Treatment, COVID-19 Serotherapy, Adenosine Monophosphate analogs & derivatives, Alanine analogs & derivatives, COVID-19 therapy, Lymphoma, Non-Hodgkin therapy, Rituximab therapeutic use
- Published
- 2021
- Full Text
- View/download PDF
43. A Severe Acute Respiratory Syndrome Coronavirus 2 detection method based on nasal and nasopharyngeal lavage fluid: A pilot feasibility study.
- Author
-
Frezza D, Fabbris C, Franz L, Vian E, Rigoli R, De Siati R, Emanuelli E, Bertinato L, Boscolo-Rizzo P, and Spinato G
- Abstract
Objective: Nose and nasopharyngeal swab is the preferred and worldwide-accepted method to detect the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) within the nose and nasopharynx. This method may be linked with possible difficulties, such as patient's discomfort or complications. This article shows a pilot study of SARS-CoV-2 detection with nasal and nasopharyngeal lavage fluids (level of evidence: 3)., Methods: Nasal lavage fluid was collected from patients who were submitted to SARS-CoV-2 screening test, due to a preceding positive rapid antigen test. A control group was enrolled among health care professionals whose nasopharyngeal swab tested negative. Nasal lavages were performed using isotonic saline solution injected through a nasal fossa. Both lavage fluid and traditional nasopharyngeal swab were analyzed by real-time (RT) PCR and antigenic test., Results: A total of 49 positive subjects were enrolled in the study. Results of the analysis on lavages and nasopharyngeal swabs were concordant for 48 cases, regardless of the antigenic and molecular test performed. RT-PCR resulted weakly positive at swab in one case and negative at lavage fluid. Among the control group (44 subjects), nasopharyngeal swab and lavage fluid analyses returned a negative result. Sensitivity of the molecular test based on nasal lavage fluid, compared to traditional nasal swab, was 97.7%, specificity was 100%, and accuracy was 98.9%, with high agreement (Cohen's κ, 0.978)., Conclusion: Nasal and nasopharyngeal lavages resulted to be highly reliable and well tolerated. A larger series is needed to confirm these results. This approach may potentially represent a valid alternative to the traditional swab method in selected cases., Level of Evidence: 3., Competing Interests: All authors declare that they have no conflict of interest., (© 2021 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.)
- Published
- 2021
- Full Text
- View/download PDF
44. Community Use of Face Masks against the Spread of COVID-19.
- Author
-
Bubbico L, Mastrangelo G, Larese-Filon F, Basso P, Rigoli R, Maurelli M, Ferlito S, Capelli M, Gisabella C, Javanbakht M, Bellizzi S, and Cegolon L
- Subjects
- Humans, Masks, SARS-CoV-2, COVID-19, Virus Diseases
- Abstract
The role of face masks to prevent and control COVID-19 is critical, especially since asymptomatic or pre-symptomatic infected individuals can shed high loads of SARS-CoV-2 in the surrounding environment. In addition to being a two-way barrier to protect against virions droplets both in terms of "source control" (for the benefits of the community) and "physical protection" (for wearer), face masks also allow maintaining physiological temperatures and humidity of the nasal cavity and mouth, independently from the external environmental conditions. Beyond compromising the viral transmission speed, exposure to cold environments could have a detrimental effect on the host's susceptibility to SARS-CoV-2. The innate human immune system becomes in fact weaker with cooler nose temperatures and thus more vulnerable to viral replication. Furthermore, there is evidence that warm, humid climates are associated with reduced spread of SARS-CoV-2, while cold dry conditions favor its stability and transmissibility. In the early stage of a viral infection, a physiological body temperature in the upper airways supports the innate immune system, endorsing the muco-ciliary clearance, inhibiting, or deactivating any first settlement of viruses. Face masks are therefore strongly recommended also outdoors, especially under cold weather conditions, not only as a physical barrier against the transmission of SARS-CoV-2, but also to prevent the rapid cooling of the nasal mucosa and the inhibition of the human innate defense of the upper airways.
- Published
- 2021
- Full Text
- View/download PDF
45. Six-Month Psychophysical Evaluation of Olfactory Dysfunction in Patients with COVID-19.
- Author
-
Boscolo-Rizzo P, Menegaldo A, Fabbris C, Spinato G, Borsetto D, Vaira LA, Calvanese L, Pettorelli A, Sonego M, Frezza D, Bertolin A, Cestaro W, Rigoli R, D'Alessandro A, Tirelli G, Da Mosto MC, Menini A, Polesel J, and Hopkins C
- Subjects
- Adult, Aged, COVID-19 diagnosis, Female, Humans, Male, Middle Aged, Olfaction Disorders diagnosis, Prospective Studies, Psychophysics, SARS-CoV-2 isolation & purification, Self Report, Smell, Taste, COVID-19 complications, COVID-19 physiopathology, Olfaction Disorders etiology, Olfaction Disorders physiopathology
- Abstract
This study prospectively assessed the 6-month prevalence of self-reported and psychophysically measured olfactory dysfunction in subjects with mild-to-moderate COVID-19. Self-reported smell or taste impairment was prospectively evaluated by SNOT-22 at diagnosis, 4-week, 8-week, and 6-month. At 6 months from the diagnosis, psychophysical evaluation of olfactory function was also performed using the 34-item culturally adapted University of Pennsylvania Smell Identification Test (CA-UPSIT). 145 completed both the 6-month subjective and psychophysical olfactory evaluation. According to CA-UPSIT, 87 subjects (60.0%) exhibited some smell dysfunction, with 10 patients being anosmic (6.9%) and seven being severely microsmic (4.8%). At the time CA-UPSIT was administered, a weak correlation was observed between the self-reported alteration of the sense of smell or taste and olfactory test scores (Spearman's r = -0.26). Among 112 patients who self-reported normal sense of smell at last follow-up, CA-UPSIT revealed normal smell in 46 (41.1%), mild microsmia in 46 (41.1%), moderate microsmia in 11 (9.8%), severe microsmia in 3 (2.3%), and anosmia in 6 (5.4%) patients; however, of those patients self-reporting normal smell but who were found to have hypofunction on testing, 62 out of 66 had a self-reported reduction in sense of smell or taste at an earlier time point. Despite most patients report a subjectively normal sense of smell, we observed a high percentage of persistent smell dysfunction at 6 months from the diagnosis of syndrome coronavirus 2 (SARS-CoV-2) infection, with 11.7% of patients being anosmic or severely microsmic. These data highlight a significant long-term rate of smell alteration in patients with previous SARS-COV-2 infection., (© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
46. Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives.
- Author
-
Felice C, Nardin C, Di Tanna GL, Grossi U, Bernardi E, Scaldaferri L, Romagnoli M, Tonon L, Cavasin P, Novello S, Scarpa R, Farnia A, De Menis E, Rigoli R, Cinetto F, Pauletto P, Agostini C, and Rattazzi M
- Subjects
- Aged, Aged, 80 and over, COVID-19, Coronavirus Infections complications, Coronavirus Infections drug therapy, Female, Humans, Hypertension drug therapy, Italy epidemiology, Male, Middle Aged, Pandemics, Pneumonia, Viral complications, Retrospective Studies, COVID-19 Drug Treatment, Angiotensin Receptor Antagonists therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Coronavirus Infections mortality, Hypertension complications, Pneumonia, Viral mortality
- Abstract
Background: The effect of chronic use of renin-angiotensin-aldosterone system (RAAS) inhibitors on the severity of COVID-19 infection is still unclear in patients with hypertension. We aimed to investigate the association between chronic use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and COVID-19-related outcomes in hypertensive patients., Methods: A single-center study was conducted on 133 consecutive hypertensive subjects presenting to the emergency department with acute respiratory symptoms and/or fever who were diagnosed with COVID-19 infection between 9 and 31 March 2020., Results: All patients were grouped according to their chronic antihypertensive medications (ACEIs, N = 40; ARBs, N = 42; not on RAAS inhibitors, N = 51). There was no statistical difference between ACEIs and ARBs groups in terms of hospital admission rate, oxygen therapy, and need for noninvasive ventilation. Patients chronically treated with RAAS inhibitors showed a significantly lower rate of admission to semi-intensive/intensive care units, when compared with the non-RAAS population (odds ratio (OR) 0.25, confidence interval (CI) 95% 0.09-0.66, P = 0.006). Similarly, the risk of mortality was lower in the former group, although not reaching statistical significance (OR 0.56, CI 95% 0.17-1.83, P = 0.341)., Conclusions: Our data suggest that chronic use of RAAS inhibitors does not negatively affect clinical course of COVID-19 in hypertensive patients. Further studies are needed to confirm this finding and determine whether RAAS inhibitors may have a protective effect on COVID-19-related morbidity and mortality., (© American Journal of Hypertension, Ltd 2020. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
47. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19.
- Author
-
Boscolo-Rizzo P, Borsetto D, Fabbris C, Spinato G, Frezza D, Menegaldo A, Mularoni F, Gaudioso P, Cazzador D, Marciani S, Frasconi S, Ferraro M, Berro C, Varago C, Nicolai P, Tirelli G, Da Mosto MC, Obholzer R, Rigoli R, Polesel J, and Hopkins C
- Subjects
- Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Humans, Italy epidemiology, Male, Middle Aged, Prevalence, Prospective Studies, Severity of Illness Index, Young Adult, COVID-19 complications, Olfaction Disorders epidemiology, Olfaction Disorders virology, Taste Disorders epidemiology, Taste Disorders virology
- Abstract
Importance: An altered sense of smell and taste has been reported to be associated with coronavirus disease 2019 (COVID-19). To understand the evolution of these symptoms during the course of the disease is important to identify patients with persistent loss of smell or taste and estimate the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the burden of olfactory and gustative dysfunctions., Objective: To evaluate the evolution of the loss of sense of smell and taste in a case series of mildly symptomatic patients with SARS-CoV-2 infection., Design, Setting, and Participants: This cross-sectional survey-based study included 202 mildly symptomatic adults (≥18 years) consecutively assessed at Treviso Regional Hospital, Italy, between March 19 and March 22, 2020, who tested positive for SARS-CoV-2 RNA by polymerase chain reaction on nasopharyngeal and throat swabs., Main Outcomes and Measures: Prevalence of altered sense of smell and taste at follow-up and their variation from baseline., Results: Of 202 patients completing the survey at baseline, 187 (92.6%) also completed the follow-up survey (103 [55.1%] women; median age, 56 years). The evaluation of the evolution of altered sense of smell or taste in the 113 patients reporting sudden onset of these symptoms at baseline showed that 55 patients (48.7%; 95% CI, 39.2-58.3) reported complete resolution of smell or taste impairment, 46 (40.7%; 95% CI, 31.6-50.4) reported an improvement in the severity, and only 12 (10.6%; 95% CI, 5.6-17.8) reported the symptom was unchanged or worse. Persistent loss of smell or taste was not associated with persistent SARS-CoV-2 infection., Conclusions and Relevance: At 4 weeks from the onset, 89% of the SARS-CoV-2-positive mildly symptomatic patients who had had a sudden onset of altered sense of smell or taste experienced a complete resolution or improvement of these symptoms. Persistent loss of smell or taste was not associated with persistent SARS-CoV-2 infection.
- Published
- 2020
- Full Text
- View/download PDF
48. Association between hepatitis C and B viruses and head and neck squamous cell carcinoma.
- Author
-
Donà S, Borsetto D, Fussey J, Biscaro V, Vian E, Spinato G, Menegaldo A, Da Mosto MC, Rigoli R, Polesel J, and Boscolo-Rizzo P
- Subjects
- Adult, Aged, Antibodies, Viral blood, Case-Control Studies, Female, Head and Neck Neoplasms epidemiology, Hepacivirus, Hepatitis B virus, Hepatitis B, Chronic epidemiology, Hepatitis B, Chronic virology, Hepatitis C, Chronic epidemiology, Hepatitis C, Chronic virology, Humans, Incidence, Italy epidemiology, Male, Middle Aged, Prevalence, Retrospective Studies, Risk Factors, Squamous Cell Carcinoma of Head and Neck epidemiology, Young Adult, Head and Neck Neoplasms virology, Hepatitis B, Chronic complications, Hepatitis C, Chronic complications, Squamous Cell Carcinoma of Head and Neck virology
- Abstract
Background: Hepatitis B and C viruses are known to be carcinogenic and have been associated with the development of non-Hodgkin's lymphoma as well as hepatocellular carcinoma. The incidence of head and neck cancer is increasing worldwide, and early diagnosis is vital in order to achieve good oncological outcomes., Objectives: To investigate the association between chronic hepatitis B and C infection, and head and neck squamous cell carcinoma (HNSCC)., Study Design: We performed a retrospective case control study with 774 head and neck squamous cell carcinoma (HNSCC) patients undergoing treatment, and 1518 cancer-free controls undergoing hernia surgery. Hepatitis B and C serologies were tested prior to treatment, and cases and controls were age- and sex-matched before analysing rates of infection., Results: HNSCC patients were more likely than controls to have evidence of chronic hepatitis B (OR = 2.76; CI 95 %, 1.64-4.64) and hepatitis C (OR = 2.59; 95 % CI, 1.46-4.60) infection. No substantial association was found between hepatitis B and C infection and other known risk factors for head and neck cancer., Conclusions: These findings suggest a positive association between both hepatitis B and hepatitis C chronic infection, and HNSCC. More work is needed to establish a causal role, however an awareness of the possibility of increased risk of HNSCC may lead to earlier diagnosis and better outcomes in patients with hepatitis B and C., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
49. Collection, transport and storage procedures for blood culture specimens in adult patients: recommendations from a board of Italian experts.
- Author
-
De Plato F, Fontana C, Gherardi G, Privitera GP, Puro V, Rigoli R, Viaggi B, and Viale P
- Subjects
- Adult, Humans, Italy, Blood Culture methods, Blood Specimen Collection methods, Quality Assurance, Health Care methods
- Abstract
Bloodstream infections (BSIs) remain a potentially life-threatening condition. The gold standard for the diagnosis of BSI is still blood cultures (BCs), and the diagnostic yield depends on clinical and technical factors that have an impact on collection and transportation. Hence, monitoring of the entire pre-analytical process from blood collection to transportation to the microbiology laboratory is critical. To optimize the clinical impact of the diagnostic and therapeutic procedures, a multidisciplinary approach and univocal protocols are mandatory. A board of specialists discussed the available evidence on the pre-analytical process and produced the present document to guide physicians and nurses on the ideal execution of BC: (1) timing and preparation for blood collection; (2) skin antisepsis; (3) blood volume; (4) sampling method and safety; (5) medium to be used; (6) time to BC transportation; and (7) quality assurance and quality management.
- Published
- 2019
- Full Text
- View/download PDF
50. Mycobacterium chimaera infections following cardiac surgery in Treviso Hospital, Italy, from 2016 to 2019: Cases report.
- Author
-
Inojosa WO, Giobbia M, Muffato G, Minniti G, Baldasso F, Carniato A, Farina F, Forner G, Rossi MC, Formentini S, Rigoli R, and Scotton PG
- Abstract
Background: An epidemic of Mycobacterium chimaera ( M. chimaera ) infections following cardiac surgery is ongoing worldwide. The outbreak was first discovered in 2011, and it has been traced to a point source contamination of the LivaNova 3T heater-cooler unit, which is used also in Italy. International data are advocated to clarify the spectrum of clinical features of the disease as well as treatment options and outcome. We report a series of M. chimaera infections diagnosed in Treviso Hospital, including the first cases notified in Italy in 2016., Case Summary: Since June 2016, we diagnosed a M. chimaera infection in nine patient who had undergone cardiac valve surgery between February 2011 and November 2016. The time between cardiac surgery and developing symptoms ranged from 6 to 97 mo. Unexplained fever, psychophysical decay, weight loss, and neurological symptoms were common complaints. The median duration of symptoms was 32 wk, and the longest was almost two years. A new cardiac murmur, splenomegaly, choroidoretinitis, anaemia or lymphopenia, abnormal liver function tests and hyponatremia were common findings. All the patients presented a prosthetic valve endocarditis, frequently associated to an ascending aortic pseudoneurysm or spondylodiscitis. M. chimaera was cultured from blood, bioprosthetic tissue, pericardial abscess, vertebral tissue, and bone marrow. Mortality is high in our series, reflecting the poor outcome observed in other reports. Three patients have undergone repeat cardiac surgery. Five patients are being treated with a targeted multidrug antimycobacterial regimen., Conclusion: Patients who have undergone cardiac surgery in Italy and presenting with signs and symptoms of endocarditis must be tested for M. chimaera ., Competing Interests: Conflict-of-interest statement: The authors declare no conflicts of interest., (©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.